参考文献/References:
[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789.
[2] Merlo M,Caiffa T,Gobbo M,et al. Reverse remodeling in dilated cardiomyopathy: insights and future perspectives[J]. Int J Cardiol Heart Vasc,2018,18:52-57.
[3] Masè M,Merlo M,Vitrella G,et al. Left ventricular reverse remodeling prediction in non-ischemic cardiomyopathy:present and perspectives[J]. Expert Rev Cardiovasc Ther,2018,16(11):771-773.
[4] Matsumura Y,Hoshikawa-Nagai E,Kubo T,et al. Left ventricular reverse remodeling in long-term (＞12 years) survivors with idiopathic dilated cardiomyopathy[J]. Am J Cardiol,2013,111(1):106-110.
[5] Kramer DG,Trikalinos TA,Kent DM,et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction:a meta-analytic approach[J]. J Am Coll Cardiol,2010,56(5):392-406.
[6] Castrichini M,Manca P,Nuzzi V,et al. Sacubitril/valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction:standard and advanced echocardiographic evidences[J]. J Clin Med,2020,9(4):906.
[7] Waring AA,Litwin SE. Redefining reverse remodeling:can echocardiography refine our ability to assess response to heart failure treatments[J]. J Am Coll Cardiol,2016,68(12):1277-1280.
[8] Barison A,Aimo A,Ortalda A,et al. Late gadolinium enhancement as a predictor of functional recovery,need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy[J]. Int J Cardiol,2018,250:195-200.
[9] 李燕,黄凌波,付兵,等. 心脏磁共振T1 Mapping技术和ECV评估扩张型心肌病心肌纤维化应用分析[J]. 中国循证心血管医学杂志,2018,10(02):185-189.
[10] Kaufmann BA,Goetschalckx K,Min SY,et al. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy[J]. Int J Cardiol,2015,191:286-293.
[11] Daubert MA,Adams K,Yow E,et al. NT-proBNP goal achievement is?associated with significant reverse?remodeling and improved clinical outcomes in HFrEF[J]. JACC Heart Fail,2019,7(2):158-168.
[12] Lupón J,Gaggin HK,de Antonio M,et al. Biomarker-assist score for reverse remodeling prediction in heart failure:the ST2-R2 score[J]. Int J Cardiol,2015,184:337-343.
[13] Gaggin HK,Szymonifka J,Bhardwaj A,et al. Head-to-head comparison of serial soluble ST2,growth differentiation factor-15,and highly-sensitive troponin T measurements in patients with chronic heart failure[J]. JACC Heart Fail,2014,2(1):65-72.
[14] Motiwala SR,Gaggin HK,Gandhi PU,et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure[J]. J Cardiovasc Transl Res,2015,8(3):164-172.
[15] Zuern CS,Floss N,Mueller II,et al. Galectin-3 is associated with left ventricular reverse remodeling and outcome after percutaneous mitral valve repair[J]. Int J Cardiol,2018,263:104-110.
[16] Karatolios K,Chatzis G,Holzendorf V,et al. Galectin-3 as a predictor of left ventricular reverse remodeling in recent-onset dilated cardiomyopathy[J]. Dis Markers,2018,2018:2958219.
[17] Iwahana T,Okada S,Kanda M,et al. Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure:a retrospective cohort study[J]. BMC Cardiovasc Disord,2020,20(1):116.
[18] Ko T,Hatano M,Komuro I. Single-cell RNA-seq of human cardiomyocytes revealed DNA damage response as a novel predictor for therapeutic prognosis in heart failure patients with dilated cardiomyopathy[J]. J Heart Lung Transplant,2020,39(4):S22-S23.
[19] Shah R,Ziegler O,Yeri A,et al. MicroRNAs associated with reverse left ventricular remodeling in humans identify pathways of heart failure progression[J]. Circ Heart Fail,2018,11(2):e004278.
[20] Groenning BA,Nilsson JC,Sondergaard L,et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure[J]. J Am Coll Cardiol,2000,36(7):2072-2080.
[21] Takemoto Y,Hozumi T,Sugioka K,et al. Beta-blocker therapy induces ventricular resynchronization in dilated cardiomyopathy with narrow QRS complex[J]. J Am Coll Cardiol,2007,49(7):778-783.
[22] Konstam MA,Kronenberg MW,Rousseau MF,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction.SOLVD (Studies of Left Ventricular Dysfunction) Investigators[J]. Circulation,1993,88(5 Pt 1):2277-2283.
[23] Wong M,Staszewsky L,Latini R,et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study[J]. J Am Coll Cardiol,2002,40(5):970-975.
[24] Martens P,Beli?n H,Dupont M,et al. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction [J]. Cardiovasc Ther,2018,36(4):e12435.
[25] Wang Y,Zhou R,Lu C,et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling:meta-analysis[J]. J Am Heart Assoc,2019,8(13):e012272.
[26] Chan AK,Sanderson JE,Wang T,et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure[J]. J Am Coll Cardiol,2007,50(7):591-596.
[27] Swedberg K,Komajda M,B?hm M,et al. Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study[J]. Lancet,2010,376(9744):875-885.
[28] Soylu K,Cerik IB,Aksan G,et al. Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart failure[J]. J Arrhythm,2020,36(4):762-767.
[29] Yin M,Wever-Pinzon O,Taleb I,et al. Reverse myocardial remodeling with centrifugal versus axial-flow left ventricular assist device in chronic heart failure patients[J]. J Heart Lung Transplant,2020,39(4):S333.
[30] Pham BN,Chaparro SV. Left ventricular assist device recovery:does duration of mechanical support matter?[J]. Heart Fail Rev,2019,24(2):237-244.
[31] Bartko PE,Arfsten H,Heitzinger G,et al. Papillary muscle dyssynchrony-mediated functional mitral regurgitation:mechanistic insights and modulation by cardiac resynchronization[J]. JACC Cardiovasc Imaging,2019,12(9):1728-1737.
[32] Zhu H,Zou T,Zhong Y,et al. Prevention of non-response to cardiac resynchronization therapy:points to remember[J]. Heart Fail Rev,2020,25(2):269-275.
[33] 黄晓凤,熊峰. 超声心动图在优化心脏再同步化治疗效果中的应用[J]. 心血管病学进展,2019,40(6):1043-1046.
[34] Edelson JB,Genuardi MV,Santangeli P,et al. Cardiac contractility monitoring: an important therapy in the treatment of advanced heart failure[J]. Curr Cardiol Rep,2020,22(9):81.
[35] Patel PA,Nadarajah R,Ali N,et al. Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction[J]. Heart Fail Rev,2021,26(2):217-226.
[36] Zhang Q,Chan YS,Liang YJ,et al. Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations[J]. Int J Cardiol,2013,167(3):889-893.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]